Abid Suddle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abid Suddle has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
Aileen Marshall
Department of Hepatology, Royal Free London NHS Trust, London, UK
3 shared publications- Oliver D. Tavabie
Leeds Teaching Hospitals NHS Trust, Leeds, UK
3 shared publications Dina Tiniakos
Newcastle University–Newcastle Campus, Newcastle upon Tyne, UK
2 shared publicationsHelen Reeves
Department of Hepatology and Liver Transplantation, The Freeman Hospital, Newcastle on Tyne, UK
2 shared publications- Kosh Agarwal
Institute of Liver Studies, King’s College Hospital NHS Foundation Trust, London, UK
2 shared publications Maria Hawkins
University College London, London, UK
2 shared publications
Latest Publications
- Open Access
- 20 May 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Transplant Indications in Polycystic Liver and Kidney Disease
Polycystic liver and kidney disease encompasses a spectrum of inherited disorders ,primarily autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD). Although many patients remain asymptomatic for decades, a subset develops debilitating complications, including massive hepatomegaly, recurrent cyst infections, malnutrition, and progressive renal dysfunction. Diagnosis relies on imaging criteria and genetic testing. ADPKD is most commonly associated with PKD1 and PKD2 mutations, whereas ADPLD is associated with PRKCSH and SEC63 mutations. Magnetic resonance imaging provides optimal assessment of cyst distribution, liver volume, and complications. Disease severity classifications, such as Schnelldorfer classification, guide therapeutic decision-making. Liver transplantation is the only definitive treatment for severe symptomatic PLD. Primary indications include recurrent cyst infections refractory to medical therapy, massive hepatomegaly with significant impairment of quality of life, malnutrition, and portal hypertension. Patient-reported instruments, including PLD-Q and POLCA, questionnaires, provide objective measures of symptom burden and aid in transplant candidacy assessment. In patients with concurrent renal insufficiency (estimated glomerular filtration rate <30 mL/min/1.73 m2), combined liver–kidney transplantation may improve outcomes and confer potential immunoprotective benefits for the renal graft. Despite favorable posttransplant outcomes—including 5-year survival rates exceeding 80%—variation in listing criteria persists, highlighting the need for standardized, evidence-based guidelines. Multidisciplinary evaluation and individualized management remain essential to optimize clinical outcomes in this complex patient population. Cite this article as: Perez-Prado S Suddle A. Transplant indications in polycystic liver and kidney disease. Turk J Gastroenterol. Published online May 20, 2026. doi: 10.5152/tjg.2026.26217
- 20 May 2026
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
Open AccessTransplant Indications in Polycystic Liver and Kidney Disease
Polycystic liver and kidney disease encompasses a spectrum of inherited disorders ,primarily autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD). Although many patients remain asymptomatic for decades, a subset develops debilitating complications, including massive hepatomegaly, recurrent cyst infections, malnutrition, and progressive renal dysfunction. Diagnosis relies on imaging criteria and genetic testing. ADPKD is most commonly associated with PKD1 and PKD2 mutations, whereas ADPLD is associated with PRKCSH and SEC63 mutations. Magnetic resonance imaging provides optimal assessment of cyst distribution, liver volume, and complications. Disease severity classifications, such as Schnelldorfer classification, guide therapeutic decision-making. Liver transplantation is the only definitive treatment for severe symptomatic PLD. Primary indications include recurrent cyst infections refractory to medical therapy, massive hepatomegaly with significant impairment of quality of life, malnutrition, and portal hypertension. Patient-reported instruments, including PLD-Q and POLCA, questionnaires, provide objective measures of symptom burden and aid in transplant candidacy assessment. In patients with concurrent renal insufficiency (estimated glomerular filtration rate <30 mL/min/1.73 m2), combined liver–kidney transplantation may improve outcomes and confer potential immunoprotective benefits for the renal graft. Despite favorable posttransplant outcomes—including 5-year survival rates exceeding 80%—variation in listing criteria persists, highlighting the need for standardized, evidence-based guidelines. Multidisciplinary evaluation and individualized management remain essential to optimize clinical outcomes in this complex patient population. Cite this article as: Perez-Prado S Suddle A. Transplant indications in polycystic liver and kidney disease. Turk J Gastroenterol. Published online May 20, 2026. doi: 10.5152/tjg.2026.26217
- Open Access
- 17 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1582
Selective Internal Radiation Therapy (SIRT) for Hepatocellular Carcinoma: Real-World Experience from a Tertiary Care Centre
Background: Selective internal radiation therapy (SIRT) with yttrium-90 microspheres has become an established locoregional treatment for hepatocellular carcinoma (HCC). Nevertheless, real-world data on clinical outcomes, including efficacy, safety, and prognostic determinants, remain limited. Methods: This study retrospectively analysed 56 patients with radiologically and/or histologically confirmed HCC who underwent SIRT at a tertiary referral centre. Baseline demographics, clinical information, tumour characteristics, procedural data, and follow-up outcomes were recorded. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary outcomes included radiological response (mRECIST), histological necrosis, and treatment-related toxicity. Prognostic pathways were explored using structural equation modelling (SEM). Results: The mean age at the beginning of SIRT was 65.0 ± 11.6 years; most patients were male (87.5%) and had preserved liver function (mean ALBI −2.9 ± 0.4). BCLC staging distribution was 50% stage A, 32.1% stage B, and 17.9% stage C. According to mRECIST criteria at 6 months, 15.2% achieved complete response (CR), 47.8% partial response (PR), 30% stable disease (SD), and 7% progressive disease (PD). Median OS was 19 months (12–32) for BCLC stage A, 28 months (3–42) for stage B, and 19 months (12–56) for stage C (log-rank p = 0.743). SEM identified diffuse tumour morphology as the most significant predictor of poor prognosis. Radical treatments were performed in 28% of patients, including four liver transplants and ten resections. Adverse events occurred in 11 patients, of which 7 were Clavien–Dindo grade I and 4 were grade II. Conclusions: In this real-world HCC group, SIRT provided durable tumour control and survival with excellent tolerability.
- 17 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (4) , 1582
Open AccessSelective Internal Radiation Therapy (SIRT) for Hepatocellular Carcinoma: Real-World Experience from a Tertiary Care Centre
Background: Selective internal radiation therapy (SIRT) with yttrium-90 microspheres has become an established locoregional treatment for hepatocellular carcinoma (HCC). Nevertheless, real-world data on clinical outcomes, including efficacy, safety, and prognostic determinants, remain limited. Methods: This study retrospectively analysed 56 patients with radiologically and/or histologically confirmed HCC who underwent SIRT at a tertiary referral centre. Baseline demographics, clinical information, tumour characteristics, procedural data, and follow-up outcomes were recorded. The primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary outcomes included radiological response (mRECIST), histological necrosis, and treatment-related toxicity. Prognostic pathways were explored using structural equation modelling (SEM). Results: The mean age at the beginning of SIRT was 65.0 ± 11.6 years; most patients were male (87.5%) and had preserved liver function (mean ALBI −2.9 ± 0.4). BCLC staging distribution was 50% stage A, 32.1% stage B, and 17.9% stage C. According to mRECIST criteria at 6 months, 15.2% achieved complete response (CR), 47.8% partial response (PR), 30% stable disease (SD), and 7% progressive disease (PD). Median OS was 19 months (12–32) for BCLC stage A, 28 months (3–42) for stage B, and 19 months (12–56) for stage C (log-rank p = 0.743). SEM identified diffuse tumour morphology as the most significant predictor of poor prognosis. Radical treatments were performed in 28% of patients, including four liver transplants and ten resections. Adverse events occurred in 11 patients, of which 7 were Clavien–Dindo grade I and 4 were grade II. Conclusions: In this real-world HCC group, SIRT provided durable tumour control and survival with excellent tolerability.
- Open Access
- 5 June 2025
- Published by BMJ in Frontline Gastroenterology
Standards for delivering ultrasound surveillance for hepatocellular cancer in the UK
Early detection of hepatocellular carcinoma (HCC) through effective surveillance is critical to improving patient outcomes. These UK national guidelines provide consensus-based standards for ultrasound (US) surveillance in individuals at risk of HCC, with the aim of enhancing diagnostic quality, consistency and service delivery. Developed by a multidisciplinary expert group, the guidelines define key components of a high-quality surveillance programme, including image acquisition protocols, structured reporting using a validated classification system, appropriate training requirements and pathways for audit and quality assurance. Emphasis is placed on equity of access, patient-centred care and improving adherence. These standards are designed to support healthcare professionals, commissioners, and service providers in delivering robust HCC surveillance across the NHS, ultimately contributing to earlier diagnosis and improved survival.
- 5 June 2025
- Published by BMJ in Frontline Gastroenterology
Open AccessStandards for delivering ultrasound surveillance for hepatocellular cancer in the UK
Early detection of hepatocellular carcinoma (HCC) through effective surveillance is critical to improving patient outcomes. These UK national guidelines provide consensus-based standards for ultrasound (US) surveillance in individuals at risk of HCC, with the aim of enhancing diagnostic quality, consistency and service delivery. Developed by a multidisciplinary expert group, the guidelines define key components of a high-quality surveillance programme, including image acquisition protocols, structured reporting using a validated classification system, appropriate training requirements and pathways for audit and quality assurance. Emphasis is placed on equity of access, patient-centred care and improving adherence. These standards are designed to support healthcare professionals, commissioners, and service providers in delivering robust HCC surveillance across the NHS, ultimately contributing to earlier diagnosis and improved survival.
- 7 May 2025
- Published by BMJ in Frontline Gastroenterology
- Vol. 16 (6) , 441-444
British Society of Gastroenterology hepatocellular carcinoma guideline review: impact on the frontline
The British Society of Gastroenterology commissioned an update on the guidelines for management of hepatocellular carcinoma (HCC) in adults at an opportune time. The incidence of and mortality from this cancer is increasing in the UK, as in other Western nations. Several clinical and scientific advances in HCC have been made in the last decade. This article, written on behalf of the HCC-UK committee, provides a commentary on the guidelines, with specific focus on areas of practice change.
- 7 May 2025
- Published by BMJ in Frontline Gastroenterology
- Vol. 16 (6) , 441-444
British Society of Gastroenterology hepatocellular carcinoma guideline review: impact on the frontline
The British Society of Gastroenterology commissioned an update on the guidelines for management of hepatocellular carcinoma (HCC) in adults at an opportune time. The incidence of and mortality from this cancer is increasing in the UK, as in other Western nations. Several clinical and scientific advances in HCC have been made in the last decade. This article, written on behalf of the HCC-UK committee, provides a commentary on the guidelines, with specific focus on areas of practice change.
- Open Access
- 11 June 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 49 (8) , 2639-2649
Clinical impact of CEUS on non-characterizable observations and observations with intermediate probability of malignancy on CT/MRI in patients at risk for HCC
Background: Hepatocellular carcinoma (HCC) is a unique cancer allowing tumor diagnosis with identification of definitive patterns of enhancement on contrast-enhanced imaging, avoiding invasive biopsy. However, it is still unclear to what extent Contrast-Enhanced Ultrasound (CEUS) is a clinically useful additional step when Computed tomography (CT) or Magnetic resonance imaging (MRI) are inconclusive. Methods: A prospective international multicenter validation study for CEUS Liver Imaging Reporting and Data System (LI-RADS) was conducted between January 2018 and August 2021. 646 patients at risk for HCC with focal liver lesions were enrolled. CEUS was performed using an intravenous ultrasound contrast agent within 4 weeks of CT/MRI. Liver nodules were categorized based on LI-RADS (LR) criteria. Histology or one-year follow-up CT/MRI imaging results were used as the reference standard. The diagnostic performance of CEUS was evaluated for inconclusive CT/MRI scan in two scenarios for which the AASLD recommends repeat imaging or imaging follow-up: observations deemed non-characterizable (LR-NC) or with indeterminate probability of malignancy (LR-3). Results: 75 observations on CT or MRI were categorized as LR-3 (n = 54) or LR-NC (n = 21) CEUS recategorization of such observations into a different LR category (namely, into one among LR-1, LR-2, LR-5, LR-M, or LR-TIV) resulted in management recommendation changes in 33.3% (25/75) and in all but one (96.0%, 24/25) observation, the new management recommendations were correct. Conclusion: CEUS LI-RADS resulted in management recommendations change in substantial number of liver observations with initial indeterminate CT/MRI characterization, identifying both non-malignant lesions and HCC, potentially accelerating the diagnostic process and alleviating the need for biopsy or follow-up imaging. ClinicalTrials.gov number, NCT03318380.
- 11 June 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 49 (8) , 2639-2649
Open AccessClinical impact of CEUS on non-characterizable observations and observations with intermediate probability of malignancy on CT/MRI in patients at risk for HCC
Background: Hepatocellular carcinoma (HCC) is a unique cancer allowing tumor diagnosis with identification of definitive patterns of enhancement on contrast-enhanced imaging, avoiding invasive biopsy. However, it is still unclear to what extent Contrast-Enhanced Ultrasound (CEUS) is a clinically useful additional step when Computed tomography (CT) or Magnetic resonance imaging (MRI) are inconclusive. Methods: A prospective international multicenter validation study for CEUS Liver Imaging Reporting and Data System (LI-RADS) was conducted between January 2018 and August 2021. 646 patients at risk for HCC with focal liver lesions were enrolled. CEUS was performed using an intravenous ultrasound contrast agent within 4 weeks of CT/MRI. Liver nodules were categorized based on LI-RADS (LR) criteria. Histology or one-year follow-up CT/MRI imaging results were used as the reference standard. The diagnostic performance of CEUS was evaluated for inconclusive CT/MRI scan in two scenarios for which the AASLD recommends repeat imaging or imaging follow-up: observations deemed non-characterizable (LR-NC) or with indeterminate probability of malignancy (LR-3). Results: 75 observations on CT or MRI were categorized as LR-3 (n = 54) or LR-NC (n = 21) CEUS recategorization of such observations into a different LR category (namely, into one among LR-1, LR-2, LR-5, LR-M, or LR-TIV) resulted in management recommendation changes in 33.3% (25/75) and in all but one (96.0%, 24/25) observation, the new management recommendations were correct. Conclusion: CEUS LI-RADS resulted in management recommendations change in substantial number of liver observations with initial indeterminate CT/MRI characterization, identifying both non-malignant lesions and HCC, potentially accelerating the diagnostic process and alleviating the need for biopsy or follow-up imaging. ClinicalTrials.gov number, NCT03318380.
- Top Cited PapersOpen Access
British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults
Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service.
Top Cited PapersOpen AccessBritish Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults
Deaths from the majority of cancers are falling globally, but the incidence and mortality from hepatocellular carcinoma (HCC) is increasing in the United Kingdom and in other Western countries. HCC is a highly fatal cancer, often diagnosed late, with an incidence to mortality ratio that approaches 1. Despite there being a number of treatment options, including those associated with good medium to long-term survival, 5-year survival from HCC in the UK remains below 20%. Sex, ethnicity and deprivation are important demographics for the incidence of, and/or survival from, HCC. These clinical practice guidelines will provide evidence-based advice for the assessment and management of patients with HCC. The clinical and scientific data underpinning the recommendations we make are summarised in detail. Much of the content will have broad relevance, but the treatment algorithms are based on therapies that are available in the UK and have regulatory approval for use in the National Health Service.
P98 Formal regional referral networks optimize patient selection for liver transplantation
Introduction Unlike other conditions with high mortality (eg hepatocellular carcinoma (HCC)) chronic liver disease (CLD) patients (PTs) in the United Kingdom do not have standardised referral pathways. To improve access to liver transplantation (LT), King’s College Hospital (KCH) developed a network of satellite LT centres (SLTCs). We aimed to evaluate the impact of SLTCs in LT candidacy evaluation in CLD PTs and those within the established HCC pathway. Methods All PTs discussed at the KCH LT meeting between 10/2014-10/2019 were included. All second opinions from other centres and PTs without CLD or HCC were excluded. Geographic, referral (KCH, SLTC or conventional referrer (CR)), clinical, demographic and laboratory data were retrospectively recorded. HCC PTs had tumor related variables recorded. CLD and HCC PTs were analyzed separately. Univariate (UVA) and multivariate analyses (MVA) were utilized to assess the impact of SLTCs. Results 1102 assessments from CLD PTs (CR=512 SLTC=299 KCH=291) and 240 assessments from HCC PTs (CR=110 SLTC=72 KCH=58) were included. HCC PTs were not significantly more likely to be; referred from CRs/SLTCs/KCH, listed or have a contraindication to LT than CLD PTs. 725 CLD PTs were listed and 216 had contraindications to LT. Variables significantly associated with listing included; younger age, autoimmune liver diseases (AILD), biliary atresia (BA), previous LT, higher CLD prognostic scores, shorter referral to decision time and referral from SLTCs. Variables significantly negatively associated with listing included; non-alcoholic fatty liver disease (NAFLD), alcohol related liver disease (ARLD), hepatitis C and referral from CRs. MVA was utilized to demonstrate that referrals from SLTCs remained independently associated with listing (adjusted odds ratio (aOR) 2.92 (95% confidence interval (CI) 2.07-4.17)). Variables associated with contraindication to LT included; older age, ARLD, NAFLD, higher CLD prognostic scores and referral from CRs. Variables negatively associated with contraindication to LT included; AILD, BA, previous LT or referral from SLTC. MVA was utilized to demonstrate that referrals from SLTC remained independently negatively associated with contraindications (aOR 0.33 (95%CI 0.21-0.50)). 168 HCC patients were listed and 55 had contraindications to LT. No variables were significantly associated with listing including referrals from SLTC on UVA or MVA. Older HCC PTs were significantly more likely to have a contraindication to LT but referrals from SLTC did not influence likelihood on UVA or MVA. Conclusions Formal referral pathways through SLTCs improve PT selection and access to LT for PTs with CLD but do not impact on the well-established HCC pathway.
P98 Formal regional referral networks optimize patient selection for liver transplantation
Introduction Unlike other conditions with high mortality (eg hepatocellular carcinoma (HCC)) chronic liver disease (CLD) patients (PTs) in the United Kingdom do not have standardised referral pathways. To improve access to liver transplantation (LT), King’s College Hospital (KCH) developed a network of satellite LT centres (SLTCs). We aimed to evaluate the impact of SLTCs in LT candidacy evaluation in CLD PTs and those within the established HCC pathway. Methods All PTs discussed at the KCH LT meeting between 10/2014-10/2019 were included. All second opinions from other centres and PTs without CLD or HCC were excluded. Geographic, referral (KCH, SLTC or conventional referrer (CR)), clinical, demographic and laboratory data were retrospectively recorded. HCC PTs had tumor related variables recorded. CLD and HCC PTs were analyzed separately. Univariate (UVA) and multivariate analyses (MVA) were utilized to assess the impact of SLTCs. Results 1102 assessments from CLD PTs (CR=512 SLTC=299 KCH=291) and 240 assessments from HCC PTs (CR=110 SLTC=72 KCH=58) were included. HCC PTs were not significantly more likely to be; referred from CRs/SLTCs/KCH, listed or have a contraindication to LT than CLD PTs. 725 CLD PTs were listed and 216 had contraindications to LT. Variables significantly associated with listing included; younger age, autoimmune liver diseases (AILD), biliary atresia (BA), previous LT, higher CLD prognostic scores, shorter referral to decision time and referral from SLTCs. Variables significantly negatively associated with listing included; non-alcoholic fatty liver disease (NAFLD), alcohol related liver disease (ARLD), hepatitis C and referral from CRs. MVA was utilized to demonstrate that referrals from SLTCs remained independently associated with listing (adjusted odds ratio (aOR) 2.92 (95% confidence interval (CI) 2.07-4.17)). Variables associated with contraindication to LT included; older age, ARLD, NAFLD, higher CLD prognostic scores and referral from CRs. Variables negatively associated with contraindication to LT included; AILD, BA, previous LT or referral from SLTC. MVA was utilized to demonstrate that referrals from SLTC remained independently negatively associated with contraindications (aOR 0.33 (95%CI 0.21-0.50)). 168 HCC patients were listed and 55 had contraindications to LT. No variables were significantly associated with listing including referrals from SLTC on UVA or MVA. Older HCC PTs were significantly more likely to have a contraindication to LT but referrals from SLTC did not influence likelihood on UVA or MVA. Conclusions Formal referral pathways through SLTCs improve PT selection and access to LT for PTs with CLD but do not impact on the well-established HCC pathway.
- Open Access
- 6 December 2019
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2019 (1) , 345-350
Management of liver complications in sickle cell disease
Liver disease is an important cause of morbidity and mortality in patients with sickle cell disease (SCD). Despite this, the natural history of liver disease is not well characterized and the evidence basis for specific therapeutic intervention is not robust. The spectrum of clinical liver disease encountered includes asymptomatic abnormalities of liver function; acute deteriorations in liver function, sometimes with a dramatic clinical phenotype; and decompensated chronic liver disease. In this paper, the pathophysiology and clinical presentation of patients with acute and chronic liver disease will be outlined. Advice will be given regarding initial assessment and investigation. The evidence for specific medical and surgical interventions will be reviewed, and management recommendations made for each specific clinical presentation. The potential role for liver transplantation will be considered in detail.
- 6 December 2019
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2019 (1) , 345-350
Open AccessManagement of liver complications in sickle cell disease
Liver disease is an important cause of morbidity and mortality in patients with sickle cell disease (SCD). Despite this, the natural history of liver disease is not well characterized and the evidence basis for specific therapeutic intervention is not robust. The spectrum of clinical liver disease encountered includes asymptomatic abnormalities of liver function; acute deteriorations in liver function, sometimes with a dramatic clinical phenotype; and decompensated chronic liver disease. In this paper, the pathophysiology and clinical presentation of patients with acute and chronic liver disease will be outlined. Advice will be given regarding initial assessment and investigation. The evidence for specific medical and surgical interventions will be reviewed, and management recommendations made for each specific clinical presentation. The potential role for liver transplantation will be considered in detail.
- 1 May 2019
- Published by Elsevier in Clinics in Liver Disease
- Vol. 23 (2) , 177-189
The Liver in Sickle Cell Disease
- 1 May 2019
- Published by Elsevier in Clinics in Liver Disease
- Vol. 23 (2) , 177-189
The Liver in Sickle Cell Disease
- 23 October 2017
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 29 (4) , 414-417
Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature
A patient with human immunodeficiency virus-1 infection presented with sub-acute liver failure, temporally related to commencement of an antiretroviral therapy regimen containing dolutegravir (Triumeq). The patient was not a carrier of HLA-B5701, and abacavir hypersensitivity was unlikely. We believe this is the first report of severe dolutegravir-related hepatotoxicity resulting in sub-acute liver failure and transplantation and highlights a potential need for closer monitoring after drug initiation.
- 23 October 2017
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 29 (4) , 414-417
Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature
A patient with human immunodeficiency virus-1 infection presented with sub-acute liver failure, temporally related to commencement of an antiretroviral therapy regimen containing dolutegravir (Triumeq). The patient was not a carrier of HLA-B5701, and abacavir hypersensitivity was unlikely. We believe this is the first report of severe dolutegravir-related hepatotoxicity resulting in sub-acute liver failure and transplantation and highlights a potential need for closer monitoring after drug initiation.